Keywords: teva, announces, conversion, period, debentures, israel-headquartered, pharmaceutical

Teva announces conversion period for debentures

Article | 11 August 2003

Israel-headquartered Teva Pharmaceutical Industries has announced that, as required by the terms under its indentures, its $360 million in principal amount ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Teva Pharmaceutical Industries

Go to company listing